TY - JOUR T1 - Learning to Personalize Medicine from Aggregate Data JF - medRxiv DO - 10.1101/2020.07.07.20148205 SP - 2020.07.07.20148205 AU - Rich Colbaugh AU - Kristin Glass Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/08/2020.07.07.20148205.abstract N2 - There is great interest in personalized medicine, in which treatment is tailored to the individual characteristics of patients. Achieving the objectives of precision healthcare will require clinically-grounded, evidence-based approaches, which in turn demands rigorous, scalable predictive analytics. Standard strategies for deriving prediction models for medicine involve acquiring ‘training’ data for large numbers of patients, labeling each patient according to the outcome of interest, and then using the labeled examples to learn to predict the outcome for new patients. Unfortunately, labeling individuals is time-consuming and expertise-intensive in medical applications and thus represents a major impediment to practical personalized medicine. We overcome this obstacle with a novel machine learning algorithm that enables individual-level prediction models to be induced from aggregate-level labeled data, which is readily-available in many health domains. The utility of the proposed learning methodology is demonstrated by: i.) leveraging US county-level mental health statistics to create a screening tool which detects individuals suffering from depression based upon their Twitter activity; ii.) designing a decision-support system that exploits aggregate clinical trials data on multiple sclerosis (MS) treatment to predict which therapy would work best for the presenting patient; iii.) employing group-level clinical trials data to induce a model able to find those MS patients likely to be helped by an experimental therapy.Competing Interest StatementKristin Glass and Rich Colbaugh are shareholders in Volv Global.Funding StatementVolv Global supported the research described in the submitted article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research reported in the submission is a retrospective study of publically available information.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in the case studies in the submitted article are available through the referenced works. ER -